^
    Back
    Association details:
    Biomarker:FGFR2 mutation
    Cancer:Endometrial Cancer
    Drug:PD173074 (Tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Drug-sensitive FGFR2 mutations in endometrial carcinoma

    Excerpt:
    Treatment of the MFE280, AN3CA, and MFE296 endometrial carcinoma cell lines harboring FGFR2 mutations with the FGFR inhibitor PD173074 (31) resulted in a marked decrease in colony formation in soft agar and cell survival in liquid culture, with IC50s in ranges of 20–30 and 2–40 nM, respectively, whereas similar treatment of the Hec-1B cell line expressing WT FGFR2 had little or no effect...
    DOI:
    https://doi.org/10.1073/pnas.0803379105